4.7 Article

Similar Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Similar Nucleocapsid Antibody Levels in People With Well-Controlled Human Immunodeficiency Virus (HIV) and a Comparable Cohort of People Without HIV

Journal

JOURNAL OF INFECTIOUS DISEASES
Volume 225, Issue 11, Pages 1937-1947

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiab616

Keywords

SARS-CoV-2; HIV; COVID-19; incidence; serology

Funding

  1. ViiV Healthcare
  2. Netherlands Organization for Health Research and Development (ZonMW) [30002000]
  3. AIDS Fonds [2009063]
  4. Gilead Sciences
  5. Janssen Pharmaceuticals
  6. Merck Sharp Dohme (MSD)

Ask authors/readers for more resources

In the Amsterdam-based AGE(h)IV Cohort Study, researchers prospectively compared the incidence and risk factors for SARS-CoV-2 infection between HIV-positive and HIV-negative participants. They found that HIV-positive individuals with suppressed viremia and adequate CD4 cell counts had similar risk of SARS-CoV-2 acquisition and similar post-infection nucleocapsid antibody levels compared to a comparable HIV-negative cohort.
Background Within the ongoing AGE(h)IV Cohort Study in Amsterdam, we prospectively compared the incidence of and risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection between human immunodeficiency virus (HIV)-positive and HIV-negative participants. Moreover, we compared SARS-CoV-2 nucleocapsid antibody levels between participants with incident infection from both groups. Methods Starting in September 2020, consenting HIV-positive and HIV-negative participants were assessed every 6 months for incident SARS-CoV-2 infection, using combined immunoglobulin (Ig) A/IgM/IgG SARS-CoV-2 nucleocapsid antibody assay. Cumulative incidence of SARS-CoV-2 infection and associated risk factors were assessed from 27 February 2020 through 30 April 2021, using complementary log-log regression. In those with incident SARS-CoV-2 infection, nucleocapsid (N) antibody levels were compared between groups using linear regression. Results The study included 241 HIV-positive (99.2% virally suppressed) and 326 HIV-negative AGE(h)IV participants. The cumulative SARS-CoV-2 incidence by April 2021 was 13.4% and 11.6% in HIV-positive and HIV-negative participants, respectively (P = .61). Younger age and African origin were independently associated with incident infection. In those with incident infection, only self-reported fever, but not HIV status, was associated with higher N antibody levels. Conclusions HIV-positive individuals with suppressed viremia and adequate CD4 cell counts had similar risk of SARS-CoV-2 acquisition and similar SARS-CoV-2 N antibody levels after infection compared with a comparable HIV-negative cohort. Human immunodeficiency virus (HIV)-positive individuals with suppressed viremia and adequate CD4 cell counts, compared with a comparable HIV-negative cohort, were not at increased risk of severe acute respiratory syndrome coronavirus 2 infection and had similar postinfection nucleocapsid antibody levels.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available